T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation

Background: Neurodegeneration with brain iron accumulation (NBIA) defines a group of genetic disorders characterized by brain iron deposition and associated with neuronal death. The known causes of NBIA include pantothenate kinase-associated neurodegeneration (PKAN), neuroferritinopathy, infantile neuroaxonal dystrophy (INAD), and aceruloplasminemia. Objective: To define the radiologic features of each NBIA subtype. Methods: Brain MRIs from patients with molecularly confirmed PKAN (26 cases), neuroferritinopathy (21 cases), INAD (four cases), and aceruloplasminemia (10 cases) were analyzed blindly to delineate patterns of iron deposition and neurodegeneration. Results: In most cases of PKAN, abnormalities were restricted to globus pallidus and substantia nigra, with 100% having an eye of the tiger sign. In a minority of PKAN cases there was hypointensity of the dentate nuclei (1/5 on T2* sequences, 2/26 on fast spin echo [FSE]). In INAD, globus pallidus and substantia nigra were involved on T2* and FSE scans, with dentate involvement only seen on T2*. By contrast, neuroferritinopathy had consistent involvement of the dentate nuclei, globus pallidus, and putamen, with confluent areas of hyperintensity due to probable cavitation, involving the pallida and putamen in 52%, and a subset having lesions in caudate nuclei and thalami. More uniform involvement of all basal ganglia and the thalami was typical in aceruloplasminemia, but without cavitation. Conclusions: In the majority of cases, different subtypes of neurodegeneration associated with brain iron accumulation can be reliably distinguished with T2* and T2 fast spin echo brain MRI, leading to accurate clinical and subsequent molecular diagnosis.

[1]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Miyajima,et al.  A case of aceruloplasminaemia: abnormal serum ceruloplasmin protein without ferroxidase activity , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  M. Argyropoulou,et al.  T2 relaxation rate of basal ganglia and cortex in patients with β-thalassaemia major , 2001 .

[4]  Kunihiro Yoshida,et al.  Aceruloplasminemia with juvenile-onset diabetes mellitus caused by exon skipping in the ceruloplasmin gene. , 2003, Internal medicine.

[5]  B. Boeve,et al.  The "eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. , 2006, Archives of neurology.

[6]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[7]  M. Berenguer,et al.  Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis. , 2005, Journal of Hepatology.

[8]  D. Birchall,et al.  Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. , 2006, Brain : a journal of neurology.

[9]  David H. Miller,et al.  Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome , 1997, Movement disorders : official journal of the Movement Disorder Society.

[10]  L. Wojtecki,et al.  Wilson's disease tremor is associated with magnetic resonance imaging lesions in basal ganglia structures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[11]  T. Kawanami,et al.  A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (HypoCPGM). , 2000, The Tohoku journal of experimental medicine.

[12]  R A Knight,et al.  MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. , 1999, Radiology.

[13]  J. Molinuevo,et al.  The eye of the tiger sign in cortical‐basal ganglionic degeneration , 1999, Movement disorders : official journal of the Movement Disorder Society.

[14]  Y. Wada,et al.  Hereditary ceruloplasmin deficiency with hemosiderosis , 1996, Human Genetics.

[15]  H. Miyajima,et al.  Late onset diabetes mellitus in patients with hereditary aceruloplasminemia. , 1996, Internal medicine.

[16]  M. Vérin,et al.  Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. , 2002, Journal of hepatology.

[17]  B. Levinson,et al.  Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. , 2003, The New England journal of medicine.

[18]  S. Hayflick.  Neurodegeneration with brain iron accumulation: from genes to pathogenesis. , 2006, Seminars in pediatric neurology.

[19]  Colin A. Johnson,et al.  Corrigendum: PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[20]  U. Bonuccelli,et al.  Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. , 2002, Blood.

[21]  Raffaella Mariani,et al.  MR imaging of cerebral cortical involvement in aceruloplasminemia. , 2005, AJNR. American journal of neuroradiology.

[22]  Colin A. Johnson,et al.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[23]  T. Montine,et al.  Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients , 2007, Magnetic resonance in medicine.

[24]  P. Riederer,et al.  Potential sources of increased iron in the substantia nigra of parkinsonian patients. , 2006, Journal of neural transmission. Supplementum.

[25]  R. Ordidge,et al.  The measurement of R2, R2* and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition. , 1997, Magnetic resonance imaging.